UCB’s performance in line with expectations for 2018

Posted by Antje Witte, Investor Relations 30-Oct-2018

Read more

Half-time analysis: UCB outlook for 2018 confirmed

Posted by Antje Witte, Investor Relations 25-Jul-2018

Read more

Three months interim report: what are the highlights?

Posted by Antje Witte, Investor Relations 25-Apr-2018

Read more

Laying a foundation for future growth

Posted by Antje Witte, Investor Relations 22-Feb-2018

Read more

2017, the story so far: Good growth leading to increased earnings outlook for 2017

Posted by Antje Witte, Investor Relations 20-Oct-2017

Read more

Strong Half Year Results improve outlook for 2017

Posted by Antje Witte, Investor Relations 27-Jul-2017

This week we have published the UCB Half Year Results and, in light of an impressive performance, we have updated the outlook for 2017.

Read more

Core medicines driving growth in 2017

Posted by Antje Witte, Investor Relations 24-Apr-2017

Read more

Financial results: achieving growth by delivering value to patients

Posted by Antje Witte, Investor Relations 23-Feb-2017

Read more

UCB continues to grow

Posted by Antje Witte, Investor Relations 25-Oct-2016

UCB’s revenue for the first nine months of 2016 show the company continuing on its growth path driven by growth of our...

Read more

UCB continues to deliver on its growth strategy

Posted by Antje Witte, Investor Relations 28-Jul-2016

It’s steady as she goes here at UCB despite the conditions outside. Our financial...

Read more